Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma

Ascierto, Paolo A.; Dummer, Reinhard; Gogas, Helen J.; Flaherty, Keith T.; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; de Groot, Jan Willem B.; Loquai, Carmen; Gollerkeri, Ashwin; Pickard, Michael D.; Robert, Caroline

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma

Autor(en):

Ascierto, Paolo A.; Dummer, Reinhard; Gogas, Helen J.; Flaherty, Keith T.; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; de Groot, Jan Willem B.; Loquai, Carmen; Gollerkeri, Ashwin; Pickard, Michael D.; Robert, Caroline

Tübinger Autor(en):

Garbe, Claus

Erschienen in:

European Journal of Cancer (2020), Bd. 126, S. 33-44

Verlagsangabe:

Elsevier Sci Ltd

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/j.ejca.2019.11.016

ISSN:

1879-0852